What is the debt of Pharmaust this year?
Pharmaust has a debt level of -1.66 AUD this year.
Pharmaust Debt 2024
Pharmaust Debt
-1.66 AUD
Ticker
PAA.AX
ISIN
AU000000PAA1
WKN
A0DNJ3
In 2024, Pharmaust's total debt was -1.66 AUD, a 60.79% change from the -1.03 AUD total debt recorded in the previous year.
Pharmaust Aktienanalyse
What does Pharmaust do?
Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Pharmaust's Debt Structure
Pharmaust's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Pharmaust's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Pharmaust’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Pharmaust’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Pharmaust stock
What was the debt of Pharmaust compared to the previous year?
The debt of Pharmaust has increased by 60.79% compared to the previous year increased.
What are the consequences of high debt for investors in Pharmaust?
High debt can pose a risk for investors of Pharmaust, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Pharmaust?
Low debt means that Pharmaust has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Pharmaust affect the company?
An increase in debt of Pharmaust can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Pharmaust affect the company?
A reduction in debt of Pharmaust can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Pharmaust?
Some factors that can influence the debt of Pharmaust include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Pharmaust so important for investors?
The debts of Pharmaust are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Pharmaust take to change the debt?
To change the debt, Pharmaust can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Pharmaust pay?
Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.
What is the dividend yield of Pharmaust?
The current dividend yield of Pharmaust is .
When does Pharmaust pay dividends?
Pharmaust pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmaust?
Pharmaust paid dividends every year for the past 0 years.
What is the dividend of Pharmaust?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmaust located?
Pharmaust is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaust from 9/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Pharmaust pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Pharmaust in the year 2023?
In the year 2023, Pharmaust distributed 0 AUD as dividends.
In which currency does Pharmaust pay out the dividend?
The dividends of Pharmaust are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaust
Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
